Cargando…

Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression

OBJECTIVE: To study the anti-inflammatory activity of fluoxetine and escitalopram in newly diagnosed patients of depression and also to evaluate the association between depression and inflammation. MATERIALS AND METHODS: Ninety-eight newly diagnosed patients of depression were recruited as cases. Fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chavda, Nilesh, Kantharia, N. D., Jaykaran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117562/
https://www.ncbi.nlm.nih.gov/pubmed/21701640
http://dx.doi.org/10.4103/0976-500X.77091
_version_ 1782206338639593472
author Chavda, Nilesh
Kantharia, N. D.
Jaykaran,
author_facet Chavda, Nilesh
Kantharia, N. D.
Jaykaran,
author_sort Chavda, Nilesh
collection PubMed
description OBJECTIVE: To study the anti-inflammatory activity of fluoxetine and escitalopram in newly diagnosed patients of depression and also to evaluate the association between depression and inflammation. MATERIALS AND METHODS: Ninety-eight newly diagnosed patients of depression were recruited as cases. From these, 48 had started treatment with fluoxetine (20 mg/day) and 50 had started treatment with escitalopram (20 mg/day). After 2 months of treatment of these patients, Hamilton rating scale for depression (HRSD scale), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and white blood cell (WBC) count were measured and compared to their respective baseline values before starting treatment. One hundred healthy volunteers were recruited as controls and their baseline of CRP, ESR and WBC count were measured and compared with their respective baseline values of cases. Severity of depression was measured by HRSD scale and anti-inflammatory activity was measured by reduction CRP, ESR and WBC count. RESULTS: On baseline comparison between cases and controls, there were significant increases in the levels of CRP (P = 0.014), ESR (P = 0.023) and WBC count (P = 0.020) in cases. In fluoxetine (20 mg/day) treatment group, there was a significant reduction in the levels of CRP (P = 0.046), ESR (P = 0.043) and WBC count (P = 0.021) after 2 months of treatment but no significant reduction in HRSD scale (P = 0.190). Similarly, in escitalopram treatment group, there was a significant reduction in CRP (P = 0.041), ESR (P = 0.030) and WBC count (P = 0.017) after 2 months of treatment but no significant reduction in HRSD scale (P = 0.169). CONCLUSION: In newly diagnosed patients of depression, inflammatory markers such as CRP, ESR and WBC count were significantly raised and Selective serotonin reuptake inhibitors SSRIs such as fluoxetine and escitalopram reduced them independent of their antidepressant effect. So, SSRIs have some anti-inflammatory activity independent of their antidepressant action.
format Online
Article
Text
id pubmed-3117562
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-31175622011-06-23 Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression Chavda, Nilesh Kantharia, N. D. Jaykaran, J Pharmacol Pharmacother Original Paper OBJECTIVE: To study the anti-inflammatory activity of fluoxetine and escitalopram in newly diagnosed patients of depression and also to evaluate the association between depression and inflammation. MATERIALS AND METHODS: Ninety-eight newly diagnosed patients of depression were recruited as cases. From these, 48 had started treatment with fluoxetine (20 mg/day) and 50 had started treatment with escitalopram (20 mg/day). After 2 months of treatment of these patients, Hamilton rating scale for depression (HRSD scale), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and white blood cell (WBC) count were measured and compared to their respective baseline values before starting treatment. One hundred healthy volunteers were recruited as controls and their baseline of CRP, ESR and WBC count were measured and compared with their respective baseline values of cases. Severity of depression was measured by HRSD scale and anti-inflammatory activity was measured by reduction CRP, ESR and WBC count. RESULTS: On baseline comparison between cases and controls, there were significant increases in the levels of CRP (P = 0.014), ESR (P = 0.023) and WBC count (P = 0.020) in cases. In fluoxetine (20 mg/day) treatment group, there was a significant reduction in the levels of CRP (P = 0.046), ESR (P = 0.043) and WBC count (P = 0.021) after 2 months of treatment but no significant reduction in HRSD scale (P = 0.190). Similarly, in escitalopram treatment group, there was a significant reduction in CRP (P = 0.041), ESR (P = 0.030) and WBC count (P = 0.017) after 2 months of treatment but no significant reduction in HRSD scale (P = 0.169). CONCLUSION: In newly diagnosed patients of depression, inflammatory markers such as CRP, ESR and WBC count were significantly raised and Selective serotonin reuptake inhibitors SSRIs such as fluoxetine and escitalopram reduced them independent of their antidepressant effect. So, SSRIs have some anti-inflammatory activity independent of their antidepressant action. Medknow Publications 2011 /pmc/articles/PMC3117562/ /pubmed/21701640 http://dx.doi.org/10.4103/0976-500X.77091 Text en © Journal of Pharmacology and Pharmacotherapeutics http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Paper
Chavda, Nilesh
Kantharia, N. D.
Jaykaran,
Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression
title Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression
title_full Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression
title_fullStr Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression
title_full_unstemmed Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression
title_short Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression
title_sort effects of fluoxetine and escitalopram on c-reactive protein in patients of depression
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117562/
https://www.ncbi.nlm.nih.gov/pubmed/21701640
http://dx.doi.org/10.4103/0976-500X.77091
work_keys_str_mv AT chavdanilesh effectsoffluoxetineandescitalopramoncreactiveproteininpatientsofdepression
AT kanthariand effectsoffluoxetineandescitalopramoncreactiveproteininpatientsofdepression
AT jaykaran effectsoffluoxetineandescitalopramoncreactiveproteininpatientsofdepression